Source comparison
BPC-157 Fibromyalgia Research Mechanism: Comparison
Angiogenesis (VEGF pathway) Upregulates VEGF-A, increases capillary density by 38% in ischaemic tissue (rodent) Reduced capillary density, elevated endothelin-1, impaired microvascular perfusion Preclinical only. No human FM trials High plausibility. Microvasc
This comparison does not assign a generated winner or score.
- Angiogenesis (VEGF pathway)
- Upregulates VEGF-A, increases capillary density by 38% in ischaemic tissue (rodent)
- Reduced capillary density, elevated endothelin-1, impaired microvascular perfusion
- Preclinical only. No human FM trials
- High plausibility. Microvascular insufficiency is documented in FM
- Mechanistically sound but untested in FM patients. Promising first-line candidate for investigational trials.
- Neuroinflammatory suppression
- Reduces TNF-α by 47%, IL-6 by 52% in colitis models; modulates NF-κB transcription
- Elevated CNS cytokines, sustained glial activation, central sensitisation
- Preclinical. Acute inflammation models only
- Moderate plausibility. FM is chronic, not acute
- Anti-inflammatory effects are robust in injury models. Translating to chronic FM requires long-term dosing studies.
- Nitric oxide stabilisation
- Enhances eNOS activity, reduces peroxynitrite damage by 34%
- Paradoxically elevated NO metabolites, oxidative stress markers
- Preclinical. Oxidative stress models
- Moderate plausibility. NO dysregulation confirmed but complex
- BPC-157 stabilises NO, not just boosts it. Could address FM's paradoxical NO profile. Hypothesis needs testing.
- Nerve regeneration (neurotrophic)
- Accelerates peripheral nerve healing, increases Schwann cell proliferation
- No documented nerve damage in FM (functional pain only)
- Preclinical. Peripheral nerve injury models
- Low plausibility. FM lacks structural nerve lesions
- Mechanism is real but may not address FM's core dysfunction. More relevant for neuropathic pain conditions.
- GABAergic modulation
- Potentiates GABA-B receptor signalling in some injury models
- Reduced GABAergic inhibition implicated in FM pain amplification
- Speculative. Limited data
- Low plausibility. Evidence is indirect
- Interesting but under-researched. Not a primary mechanism for BPC-157.